关键词:

"> font-size:10.5pt, ">卵巢癌, 基质金属蛋白酶9, 基因多态性, 疗效

Abstract:

Objective： To evaluate the relationship between polymorphisms of matrix metalloproteinase 9（MMP-9） rs3918249/rs3918241 and the short-term efficacy of TP regimen in ovarian cancer. Methods： A total of 109 ovarian cancer patients who were pathologically diagnosed and received first-line TP treatment with complete data were included in the study. Blood samples were collected， and DNA was extracted and sequenced by high-throughput sequencing to identify the genotypes of rs3918249 and rs3918241， and their correlation with the efficacy of TP regimen was analyzed. Results： Among the 109 patients， 78 patients had complete or partial response （CR/PR group）， and 31 patients had stable disease or progressive disease（SD/PD group） after treatment. The frequency distribution of rs3918241 allele between the two groups was statistically significant （P<0.05）. The objective response rate was 3.172 times higher （95%CI： 1.064-9.459） in patients carrying the A allele than those carrying the T allele. Conclusion：Advanced ovarian cancer patients carrying rs3918241 A allele have better short-term efficacy when treated with TP regimen.

Key words:

"> font-size:10.5pt, ">ovarian cancer, matrix metalloproteinase 9, polymorphisms, curative effect